In a small Tennessee household, the usual political divide has given way to a rare point of agreement. Amye and Charlie Joseph have been married for 35 years, yet they sit on opposite ends of the American political spectrum—she is a Republican, he is a Democrat. But when the conversation turns to the rising cost of prescription drugs, the partisan gap disappears. Both share a deep frustration with pharmacy benefit managers, the little-known healthcare middlemen that have become a surprising target of bipartisan anger across the country.
Pharmacy benefit managers, commonly known as PBMs, were originally designed to serve as intermediaries between insurance companies, drug manufacturers, and pharmacies. Their stated purpose was to negotiate lower drug prices on behalf of employers and health plans, using their purchasing power to extract discounts from pharmaceutical companies. Over time, however, these companies have grown into powerful conglomerates that critics say prioritize their own profits over the interests of patients and the public.
The Josephs' frustration centers on CVS Health, a massive healthcare corporation that reported $400 billion in revenue last year. CVS Health is not just a pharmacy chain—it owns Aetna, one of the nation's largest health insurers, operates CVS Caremark, one of the dominant PBMs in the country, and runs the largest retail pharmacy network in America. This vertical integration means the same company can decide which drugs are covered, negotiate their prices, and sell them at its own stores, a arrangement that critics argue creates inherent conflicts of interest.
For Amye Joseph, the problem is personal. She describes a healthcare experience stripped of human connection, where pharmacists are no longer accessible for face-to-face consultations and drug prices seem to climb without clear justification. She also resents pressure from the couple's CVS Caremark drug plan to fill prescriptions at CVS stores rather than at their preferred local pharmacy. Her conclusion is blunt: the company is not acting as a neutral middleman but as a "money grab" for its own corporate parent.
That sentiment is hardly isolated. Across party lines, patients, politicians, and employers have increasingly trained their ire on PBMs, accusing them of inflating costs while pocketing profits at the expense of everyone else in the healthcare system. The issue has become a rare unifying cause in Washington, D.C., where Democrats and Republicans otherwise remain deeply divided on how to reform American healthcare.
In Tennessee and Arkansas, that frustration has translated into action. State lawmakers have begun regulating PBMs directly, a move that reflects growing impatience with federal inaction on the issue. These state-level efforts are part of a broader trend, as legislatures across the country search for ways to rein in healthcare costs that consumers feel acutely at the pharmacy counter. The regulations aim to increase transparency, curb practices that steer patients toward affiliated pharmacies, and ensure that PBM contracts do not disadvantage independent drugstores.
The push for reform has been fueled by stories like the Josephs', which illustrate how drug pricing decisions made by distant corporations can affect everyday families. When a PBM decides which medications are covered, how much patients pay out of pocket, and which pharmacies can dispense those drugs, the consequences ripple through households already struggling with rising premiums and deductibles. For many Americans, the pharmacy has become the most visible front in the battle over healthcare affordability.
Critics of PBMs argue that the industry's business model has strayed far from its original mission. Instead of simply negotiating discounts, PBMs now employ complex spread pricing arrangements and rebate systems that obscure the true cost of drugs. These practices can leave employers and patients paying more while PBMs retain a substantial share of the savings they claim to generate. The lack of transparency has made it difficult for outsiders to determine exactly how much money is flowing where.
Defenders of PBMs contend that they play a necessary role in containing drug costs by counterbalancing the pricing power of pharmaceutical manufacturers. Without them, they argue, drug companies would face little resistance in setting high prices. But even some industry observers acknowledge that consolidation among PBMs has reduced competition and given a handful of companies enormous leverage over the entire supply chain.
The bipartisan nature of the backlash is what makes the current moment unusual. In an era when healthcare debates often split along ideological lines—with Democrats favoring government intervention and Republicans advocating market-based solutions—taking on PBMs has become a shared cause. Both sides can point to constituents who feel cheated by a system that seems rigged against them, whether they live in a red state or a blue one.
The Josephs embody this dynamic. Their marriage has survived 35 years of political differences, but their shared disdain for PBMs has become a kind of common ground. Charlie Joseph, the Democrat, and Amye Joseph, the Republican, may disagree on taxes, social policy, and the role of government, but they agree that the current pharmacy benefit system is failing patients.
That convergence of opinion is now playing out in statehouses and on Capitol Hill. Lawmakers from both parties have introduced bills aimed at increasing PBM transparency, banning certain pricing practices, and requiring greater disclosure of rebates and fees. While the specifics vary, the underlying message is consistent: voters want action, and they are not particularly interested in partisan labels when it comes to the cost of their medications.
The stakes extend beyond individual households. Employers that sponsor health plans, especially small businesses, say PBM practices can make it difficult to predict and control healthcare spending. Independent pharmacists argue that they are being squeezed out of business by unfair reimbursement rates and contract terms that favor large chain pharmacies affiliated with the same companies that manage benefits. Patients, meanwhile, face higher out-of-pocket costs and fewer choices about where to fill their prescriptions.
As the debate moves forward, the challenge will be translating widespread frustration into effective policy. Regulating PBMs is technically complex, and the industry has significant resources to push back against changes that threaten its bottom line. Yet the political pressure is mounting, and the unusual alliance between Republicans and Democrats suggests that the days of ignoring the issue may be coming to an end.
For the Josephs, the hope is that their shared frustration will eventually yield results. They represent a growing number of Americans who say the current system is not working—and who are looking for leaders willing to take on the powerful companies in the middle. Whether that pressure leads to meaningful reform at the state or federal level remains to be seen, but the bipartisan anger over pharmacy benefit managers is no longer a quiet complaint. It is now a movement.
(0)